Chronic lymphocytic leukemia (CLL) accounts for the vast majority of cases of leukemia.
Patients of advanced age are more likely to develop the condition, which has a highly varied …

Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …

Hematologic malignancies are among the most common cancers, and understanding their
incidence and death is crucial for targeting prevention, clinical practice improvement, and …

EBV-associated lymphoproliferative disorders (LPD) include conditions of B, T, and NK cell
derivation with a wide clinicopathological spectrum ranging from indolent, self-limiting, and …

Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as Bruton …

Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐
cell neoplasms involving the skin, the majority of which may be classified as Mycosis …

Plasma cell neoplasms including multiple myeloma (MM) and related terminally
differentiated B-cell neoplasms are characterized by secretion of monoclonal …